erbB2 is required for G protein-coupled receptor signaling in the heart

Abstract

erbB2͞Her2, a ligandless receptor kinase, has pleiotropic effects on mammalian development and human disease. The absence of erbB2 signaling in cardiac myocytes results in dilated cardiomyopathy in mice, resembling the cardiotoxic effects observed in a subset of breast cancer patients treated with the anti-Her2 antibody herceptin. Emerging evidence suggests that erbB2 is pivotal for integrating signaling networks involving multiple classes of extracellular signals. However, its role in G protein-coupled receptor (GPCR) signaling remains undefined. Because the activation of the MAPK pathway through GPCR signaling is important for cardiac homeostasis, we investigated whether erbB2 is required for GPCR-mediated MAPK signaling in wild-type and heart-specific erbB2 mutant mice. Here we demonstrate that erbB2, but not EGF receptor, is essential for MAPK activation induced by multiple GPCR agonists in cardiac myocytes. erbB2 is immunocomplexed with a GPCR in vivo and is transactivated after ligand treatment in vitro. Coexpression of erbB2 with GPCRs in heterologous cells results in ligand-dependent complex formation and MAPK activation. Furthermore, MAPK activation and cardiac contractility are markedly impaired in heart-specific erbB2 mutants infused with a GPCR agonist. These results reveal an essential mechanism requiring erbB2 as a coreceptor for GPCR signaling in the heart. The obligatory role of erbB2 in GPCR-dependent signaling may also be important in other cellular systems.MAPK ͉ cardiac myocytes ͉ erbB2 mutants

A functional siRNA screen identifies genes modulating angiotensin II-mediated EGFR transactivation

“…Although in a way expected, this observation provided important confidence and validation that the screen was sufficiently powerful to interrogate AT 1 R-EGFR transactivation. The finding that ErbB2 (the common dimerising partner for ErbB receptors) modulates the AT 1 R-EGFR transactivation response in our mammary epithelial cell model is consistent with previous studies suggesting that ErbB2 is required for AngII-mediated EGFR transactivation (Chan et al, 2006;Negro et al, 2006). It also corroborates data from other GPCRs, for example, the thrombin-dependent PAR1 activation in MDA-MB-231 breast cancer cells that transactivates EGFRErbB2 and increases cell invasiveness (Arora et al, 2008).…”

The β2-adrenergic receptor and Her2 comprise a positive feedback loop in human breast cancer cells

“…A previous study has shown that Her2 could form a complex with b2-AR in the heart and brain, which was required for MAPK activation induced by multiple GPCR agonists in cardiac myocytes [17]. It indicated that Her2 receptor could also be transactivated in response to GPCR ligand stimulation.…”

Neuregulin1-ErbB Signaling in Doxorubicin-Induced Cardiotoxicity

“…In addition, the ErbB signaling can be regulated by G-protein coupled receptors (GPCRs). Studies have shown that thrombin and endothelin have positive effects on the ErbB signaling via activation of matrix metalloproteinases (MMPs), subsequent activation of ErbB ligands, or activation of Src or Pyk2 which phosphorylate ErbB receptors (Dikic et al, 1996;Yarden and Sliwkowski, 2001b;Negro et al, 2006).…”